What Does Society Value About Cancer Medicines? A Discrete Choice Experiment in the Belgian Population

Kim Pauwels, Isabelle Huys, Minne Casteels, Yvonne Denier, Martina Vandebroek and Steven Simoens ()
Additional contact information
Kim Pauwels: KU Leuven
Isabelle Huys: KU Leuven
Minne Casteels: KU Leuven
Yvonne Denier: KU Leuven
Martina Vandebroek: KU Leuven
Steven Simoens: KU Leuven

Applied Health Economics and Health Policy, 2019, vol. 17, issue 6, No 13, 895-902

Abstract: Abstract Background Debate on pricing and reimbursement of cancer medicines highlights the need to establish the value of cancer medicines. Objective This study aims to elicit the trade-offs in cancer medicine characteristics that the Belgian population is willing to make. Methods A discrete choice experiment used six attributes with three levels each, based on literature and focus group discussions. The survey was sent to a random sample of 3500 Belgian citizens. Based on the choice of 961 respondents, individual parameters were estimated with a mixed logit model. Results Societal value of cancer medicines was positively affected by a higher number of patients eligible for treatment, a high initial life expectancy and quality of life of patients, a high gain in quality of life and life expectancy due to treatment, and a low treatment cost. The value of 1-year gain in life expectancy was independent from the initial life expectancy of the patient. However, the value of one-point gain in quality of life was higher for patients with a low initial quality of life than for patients with a high initial quality of life. Conclusions This study has shown that gain in quality of life with cancer medicines is valued higher by Belgian society for patients who have lower initial quality of life before the start of treatment.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-019-00504-4 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:17:y:2019:i:6:d:10.1007_s40258-019-00504-4

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-019-00504-4

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().